The Company's consolidated financial statements
for the second quarter of 2022 has been approved by
the Board of Directors.
Date of events
2022/08/03
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/03
2.Date of the audit committee approved:2022/08/03
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):255,346
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):82,440
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):10,688
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):25,190
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):19,946
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):20,234
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.95
11.Total assets end of the period (thousand NTD):842,926
12.Total liabilities end of the period
(thousand NTD):240,235
13.Equity attributable to owners of parent end of the
period (thousand NTD):602,945
14.Any other matters that need to be specified:NONE
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sofiva Genomics Co. Ltd. published this content on 03 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2022 07:31:07 UTC.
Sofiva Genomics Co Ltd is a Taiwan-based company mainly engaged in provision of deoxyribonucleic acid (DNA) testing services. The Company's DNA testing services mainly contain reproductive medicine testing, pregnant women testing, newborn testing, rare disease genetic testing, personalized genetic testing, cancer genetic testing, and genetic counseling services. Reproductive Medicine testing is pre-implantation genetic diagnosis for embryos. Pregnant women testing services predict the occurrence of preeclampsia and provide prenatal diagnosis. Neonatal testing services provide neonatal hearing loss genetic test, respiratory distress syndrome test, congenital cytomegalovirus infection test service. Personalized genetic testing services includes human papilloma virus screening, paternity testing, telomere testing, chronic disease and cardiovascular disease and other genetic research. Cancer genetic testing services is applied to cancer patients.